Cargando…
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature
INTRODUCTION: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs...
Autores principales: | van der Hilst, Jeroen CH, Moutschen, Michel, Messiaen, Peter E, Lauwerys, Bernard R, Vanderschueren, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831592/ https://www.ncbi.nlm.nih.gov/pubmed/27110096 http://dx.doi.org/10.2147/BTT.S102954 |
Ejemplares similares
-
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020) -
IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
por: Köhler, Birgit Maria, et al.
Publicado: (2018) -
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020) -
Familial Mediterranean Fever without Fever
por: Hotta, Yuma, et al.
Publicado: (2020) -
Anti-CCP Antibodies Are Not Associated with Familial Mediterranean Fever in Childhood
por: Onur, Hatice, et al.
Publicado: (2013)